Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine

Journal of Gastroenterology

Volumn 39, Issue 1, 2004, Pages 34-40

  Matsuda, Marie ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Tsubota, Akihito ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Someya, Takashi ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Satoh, Junko ^a   Takagi, Kimiko ^a   Kobayashi, Mariko ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hepatitis B virus; Lamivudine; YMDD mutant

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STRUCTURAL GENE; VIRUS CARRIER; VIRUS RESISTANCE;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA-DIRECTED DNA POLYMERASE;

EID: 10744225065     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1242-4     Document Type: Article

References (18)

1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A 1-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
2. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
3. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, et al. Histological changes in liver biopsies after 1 year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-8.
4. Tsubota A, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. Am J Gastroenterol 2001;96:557-62.
5. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
6. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-5.
7. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DLJ, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7.
8. Lau DTY, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
9. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
10. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002;37:824-30.
11. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-6.
12. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol Res 2000;17:31-42.
13. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, et al. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 1999;37:310-4.
14. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir Dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
15. Someya T, Suzuki Y, Arase Y, Kobayashi M, Suzuki F, Tsubota A, et al. Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant. J Gastroenterol 2001;36:133-6.
16. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 2002;37:922-7.
17. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002;37:259-65.
18. Paik YH, Chung HY, Ryu WS, Lee KS, Lee JS, Jung Kim JH, et al. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol 2001;35:92-8.